Genomma Lab InternacionalB de CVMEX:LABB +2.59%66 ROC (Joel Greenblatt) % is 35.35% as of Mar. 2026, which is 2% below its 10-year median of 35.98. GuruFocus rates MEX:LABB with a GF Score™ of 66/100 and a GF Value™ of MXN17.64 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 978 Drug Manufacturers companies, Genomma Lab InternacionalB de CV ranks better than 78.32% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Genomma Lab InternacionalB de CV's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 35.35%.
The historical rank and industry rank for Genomma Lab InternacionalB de CV's ROC (Joel Greenblatt) % or its related term are showing as below:
MEX:LABB'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -33.79 Med: 35.98 Max: 75.43
Current: 35.34
During the past 13 years, Genomma Lab InternacionalB de CV's highest ROC (Joel Greenblatt) % was 75.43%. The lowest was -33.79%. And the median was 35.98%.
MEX:LABB's ROC (Joel Greenblatt) % is ranked better than 78.32% of 978
companies
in the Drug Manufacturers industry
Industry Median: 11.32
vs MEX:LABB: 35.34
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomma Lab InternacionalB de CV ROC (Joel Greenblatt) % Chart
MEX:LABB vs ZTS, UTHR, VTRS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomma Lab InternacionalB de CV ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Genomma Lab InternacionalB de CV's ROC (Joel Greenblatt) % falls into.
Genomma Lab InternacionalB de CV ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 35.35% mean?
Genomma Lab InternacionalB de CV (MEX:LABB) has a ROC (Joel Greenblatt) % of 35.35% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Genomma Lab InternacionalB de CV and its competitors. This is near median its historical median of 35.98. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #212 out of 978 companies in the Drug Manufacturers industry, placing it in the top 21.7%.
Is Genomma Lab InternacionalB de CV's ROC (Joel Greenblatt) % too high?
Genomma Lab InternacionalB de CV's current ROC (Joel Greenblatt) % of 35.35% is near median its 10-year median of 35.98. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.32. Genomma Lab InternacionalB de CV's value of 35.35% is 212.3% above this industry median. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #212 out of 978 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #212 out of 978 companies for ROC (Joel Greenblatt) %. This places Genomma Lab InternacionalB de CV in the top 22% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 11.32. Genomma Lab InternacionalB de CV's value of 35.35% is 212.3% above this benchmark. While the company's 10-year median is 35.98 vs. the industry median of 11.32, Genomma Lab InternacionalB de CV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.32, based on 978 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomma Lab InternacionalB de CV's current ROC (Joel Greenblatt) % of 35.35% is 212.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Genomma Lab InternacionalB de CV and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomma Lab InternacionalB de CV's current ROC (Joel Greenblatt) % is 35.35%, which is near median its own 10-year median of 35.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.64, compared to a current price of MXN15.04 — trading 14.7% below its estimated fair value. The current ROC (Joel Greenblatt) % is 35.35%, which is near median its 10-year median of 35.98 and 212.3% above the Drug Manufacturers industry median of 11.32. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current ROC (Joel Greenblatt) % is 35.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued.
The current stock price of MXN15.04 is trading 14.7% below its estimated GF Value™ of MXN17.64.
GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.
Key valuation signals for MEX:LABB:
ROC (Joel Greenblatt) %: 35.35% (near median its 10-year median of 35.98)
GF Value™: MXN17.64 vs. price of MXN15.04 (14.7% below fair value)
Industry Position: 212.3% above the Drug Manufacturers median (#212 of 978)
No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomma Lab InternacionalB de CV Business Description
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score
Get the complete analysis for MEX:LABB
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:LABB has been successfully added to your 
